Christopher Durant Turner
Chief Medical Officer · Nuvalent, Inc.
- 2026
- Jul 15, 2026
- 2
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher Durant Turner files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- James E. Flynn - $70.87M in NUVL purchases and sales in the last 12 months
- James Richard Porter - $20.62M in NUVL purchases and sales in the last 12 months
- Deborah Ann Miller - $13.40M in NUVL purchases and sales in the last 12 months
- Alexandra Balcom - $11.05M in NUVL purchases and sales in the last 12 months
- Darlene Noci - $10.75M in NUVL purchases and sales in the last 12 months
- Matthew Shair - $6.84M in NUVL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Durant Turner?
Christopher Durant Turner is a corporate insider, tracked as Chief Medical Officer of Nuvalent, Inc. (NUVL). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Christopher Durant Turner last file a Form 4?
The most recent primary Form 4 on record is dated 15 July 2026, one of 2 filings going back to 2026.
Has Christopher Durant Turner been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($721K) across all tracked filings.
